Amarin Corp Plcuk (AMRN) Net Cash Flow (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Net Cash Flow of -$3.6 million for Q1 2026, down 137.58% year-over-year from $9.6 million in Q1 2025, and down 130.59% quarter-over-quarter from $11.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Net Cash Flow (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Net Cash Flow data on file, last reported at -$3.6 million in Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$3.6 million, down 137.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 million (up 112.09% YoY), and the FY2025 annual result was $13.5 million, up 117.24% from the prior year.
- Net Cash Flow eased to -$3.6 million in Q1 2026 per AMRN's latest filing, from $11.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $41.6 million in Q2 2023 and troughed at -$71.6 million in Q4 2023.
- A 5-year average of -$5.4 million and a median of -$303000.0 in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 8564.69% in 2023, then soared 1331.97% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$26.2 million in 2022, then sank by 172.83% to -$71.6 million in 2023, then surged by 49.51% to -$36.1 million in 2024, then surged by 132.54% to $11.8 million in 2025, then slumped by 130.59% to -$3.6 million in 2026.
- Business Quant data shows AMRN's Net Cash Flow at -$3.6 million in Q1 2026, $11.8 million in Q4 2025, and -$25.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | -3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.60 Mn |
| Mar 31, 2026 | -3.60 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Sep 30, 2025 | -25.07 Mn |
| Sep 30, 2025 | -25.07 Mn |
| Jun 30, 2025 | 28.35 Mn |
| Jun 30, 2025 | 28.35 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Dec 31, 2024 | -36.13 Mn |
| Dec 31, 2024 | -36.13 Mn |
| Sep 30, 2024 | -58.98 Mn |
| Sep 30, 2024 | -58.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 14.69 Mn |
| Mar 31, 2024 | 14.69 Mn |
| Dec 31, 2023 | -71.56 Mn |
| Dec 31, 2023 | -71.56 Mn |